News for Cerevel Therapeutics Holdings, Inc. (CERE)

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behal

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (: ABBV).

PR NewswireNEW YORK, April 17, 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Ther

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed against Cerevel Therapeutics Holdings, Inc. (”œC

NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behal

PR NewswireLOS ANGELES, April 11, 2025 LOS ANGELES, April 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remi

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all persons or entities that: (1) sold or oth

PR NewswireSAN DIEGO, April 4, 2025 SAN DIEGO, April 4, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed against Cerevel

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Th

AbbVie Inc. (ABBV) has announced a significant financial adjustment, revealing a $3.5 billion impairment charge related to its emraclidine intangible asset. T

Overview of the Recent Transaction On October 21, 2024, Perceptive Advisors LLC, a prominent investment firm, initiated a new position in Inhibikase Therapeutic

Overview of the Recent Transaction On October 14, 2024, Perceptive Advisors LLC, a prominent investment firm, executed a significant transaction by purchasing 8

High-rolling investors have positioned themselves bearish on Cerevel Therapeutics Hldg CERE, and it's important for retail traders to take note. \This activity ...

We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where Cerevel Therapeutics Holdings, Inc.

Balyasny Asset Management and Schonfeld Strategic Advisors are parting ways with some of their traders specializing in mergers and acquisitions, people familiar with the matter said, amid ongoing challenges in the global dealmaking environment.

According to Michael Adams, the Lead Editor of Investing at Forbes, investments in healthcare stocks provide investors with consistent and steady returns because of the defensive nature of these stocks...

Cerevel Shareholders are encouraged to contact BFA Law about their rights relating to the upcoming merger....

CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel's $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the Firm